Alzamend Neuro Stock Buy Hold or Sell Recommendation
| ALZN Stock | USD 0.69 0.01 1.47% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Alzamend Neuro is 'Strong Sell'. Macroaxis provides Alzamend Neuro buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ALZN positions. The advice algorithm takes into account all of Alzamend Neuro's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Alzamend Neuro's buy or sell advice are summarized below:
Real Value 1.52 | Target Price 4 | Hype Value 0.67 | Market Value 0.69 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Alzamend Neuro given historical horizon and risk tolerance towards Alzamend Neuro. When Macroaxis issues a 'buy' or 'sell' recommendation for Alzamend Neuro, the advice is generated through an automated system that utilizes algorithms and statistical models.
Alzamend |
Execute Alzamend Neuro Buy or Sell Advice
The Alzamend recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Alzamend Neuro. Macroaxis does not own or have any residual interests in Alzamend Neuro or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Alzamend Neuro's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Alzamend Neuro Trading Alerts and Improvement Suggestions
| Alzamend Neuro generated a negative expected return over the last 90 days | |
| Alzamend Neuro has high historical volatility and very poor performance | |
| Alzamend Neuro has some characteristics of a very speculative penny stock | |
| Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.88 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alzamend Neuro currently holds about 11.53 M in cash with (8.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Alzamend Neuro has a poor financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Alzamend Neuro shares target cut, retains buy rating - Investing.com UK |
Alzamend Neuro Returns Distribution Density
The distribution of Alzamend Neuro's historical returns is an attempt to chart the uncertainty of Alzamend Neuro's future price movements. The chart of the probability distribution of Alzamend Neuro daily returns describes the distribution of returns around its average expected value. We use Alzamend Neuro price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Alzamend Neuro returns is essential to provide solid investment advice for Alzamend Neuro.
| Mean Return | -0.29 | Value At Risk | -7.62 | Potential Upside | 7.41 | Standard Deviation | 5.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Alzamend Neuro historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Alzamend Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alzamend Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alzamend Neuro backward and forwards among themselves. Alzamend Neuro's institutional investor refers to the entity that pools money to purchase Alzamend Neuro's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 66.0 | Bank Of America Corp | 2023-12-31 | 47.0 | Wells Fargo & Co | 2023-12-31 | 35.0 | Parallel Advisors, Llc | 2023-12-31 | 33.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 33.0 | Bank Of New York Mellon Corp | 2023-12-31 | 0.0 | Insight Wealth Strategies, Lp | 2023-12-31 | 0.0 | Group One Trading, Lp | 2023-09-30 | 0.0 | Foundations Investment Advisors, Llc | 2023-12-31 | 0.0 | Bb&t Corp. | 2023-12-31 | 154.3 K | Vanguard Group Inc | 2023-12-31 | 78.5 K |
Alzamend Neuro Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 47.7K | 1.8M | 12.1M | (8.9M) | (8.0M) | (7.6M) | |
| Net Borrowings | 72.7K | (16.7K) | 2.3M | (58.7K) | (67.5K) | (64.1K) | |
| Net Income | (4.4M) | (5.0M) | (12.4M) | (14.9M) | (13.4M) | (12.7M) | |
| Change To Netincome | 2.4M | 2.5M | 4.4M | 3.6M | 4.1M | 2.5M | |
| End Period Cash Flow | 90.3K | 1.9M | 14.1M | 5.1M | 5.9M | 4.0M | |
| Investments | 105K | 100.9K | (106.5K) | (147.2K) | (132.5K) | (125.9K) | |
| Free Cash Flow | (2.3M) | (2.7M) | (6.7M) | (8.9M) | (8.0M) | (7.6M) | |
| Other Non Cash Items | 562.3K | 454.6K | 8.8K | 1.7M | 1.5M | 787.9K |
Alzamend Neuro Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Alzamend Neuro or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Alzamend Neuro's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Alzamend stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.34 | |
β | Beta against NYSE Composite | 0.50 | |
σ | Overall volatility | 5.26 | |
Ir | Information ratio | -0.07 |
Alzamend Neuro Volatility Alert
Alzamend Neuro exhibits very low volatility with skewness of 0.79 and kurtosis of 4.01. Alzamend Neuro is a potential penny stock. Although Alzamend Neuro may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Alzamend Neuro. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Alzamend instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Alzamend Neuro Fundamentals Vs Peers
Comparing Alzamend Neuro's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Alzamend Neuro's direct or indirect competition across all of the common fundamentals between Alzamend Neuro and the related equities. This way, we can detect undervalued stocks with similar characteristics as Alzamend Neuro or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Alzamend Neuro's fundamental indicators could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Alzamend Neuro to competition |
| Fundamentals | Alzamend Neuro | Peer Average |
| Return On Equity | -11.96 | -0.31 |
| Return On Asset | -1.67 | -0.14 |
| Current Valuation | 4.83 M | 16.62 B |
| Shares Outstanding | 6.87 M | 571.82 M |
| Shares Owned By Insiders | 29.63 % | 10.09 % |
| Shares Owned By Institutions | 5.45 % | 39.21 % |
| Number Of Shares Shorted | 45.31 K | 4.71 M |
| Price To Book | 7.23 X | 9.51 X |
| EBITDA | (14.85 M) | 3.9 B |
| Net Income | (14.88 M) | 570.98 M |
| Cash And Equivalents | 11.53 M | 2.7 B |
| Cash Per Share | 0.12 X | 5.01 X |
| Total Debt | 2.08 K | 5.32 B |
| Current Ratio | 11.78 X | 2.16 X |
| Book Value Per Share | (0.63) X | 1.93 K |
| Cash Flow From Operations | (8.92 M) | 971.22 M |
| Short Ratio | 0.47 X | 4.00 X |
| Earnings Per Share | (1.82) X | 3.12 X |
| Target Price | 21.0 | |
| Number Of Employees | 4 | 18.84 K |
| Beta | 0.021 | -0.15 |
| Market Capitalization | 4.7 M | 19.03 B |
| Total Asset | 5.92 M | 29.47 B |
| Retained Earnings | (44.07 M) | 9.33 B |
| Working Capital | 2.97 M | 1.48 B |
| Net Asset | 5.92 M |
Note: Acquisition by Ault Milton C Iii of 334 shares of Alzamend Neuro at 0.9109 subject to Rule 16b-3 [view details]
Alzamend Neuro Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Alzamend . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Alzamend Neuro Buy or Sell Advice
When is the right time to buy or sell Alzamend Neuro? Buying financial instruments such as Alzamend Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2023 | 2024 (projected) | Deferred Long Term Liabilities | 67.5K | 60K | Net Receivables | 14.6K | 13.9K |
Use Investing Ideas to Build Portfolios
In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Alzamend Neuro Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.Note that the Alzamend Neuro information on this page should be used as a complementary analysis to other Alzamend Neuro's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Alzamend Stock analysis
When running Alzamend Neuro's price analysis, check to measure Alzamend Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alzamend Neuro is operating at the current time. Most of Alzamend Neuro's value examination focuses on studying past and present price action to predict the probability of Alzamend Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alzamend Neuro's price. Additionally, you may evaluate how the addition of Alzamend Neuro to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Alzamend Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Return On Assets (1.67) | Return On Equity (11.96) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.